List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/9333278/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Brief report on a phase I/IIa study to assess the safety, tolerability, and immune response of AGMG0201 in patients with essential hypertension. Hypertension Research, 2022, 45, 61-65.	2.7	8
2	Effect of prorenin peptide vaccine on the early phase of diabetic retinopathy in a murine model of type 2 diabetes. PLoS ONE, 2022, 17, e0262568.	2.5	2
3	RANKL Impairs the TLR4 Pathway by Increasing TRAF6 and RANK Interaction in Macrophages. BioMed Research International, 2022, 2022, 1-13.	1.9	3
4	Preclinical study of a DNA vaccine targeting SARS-CoV-2. Current Research in Translational Medicine, 2022, 70, 103348.	1.8	9
5	A novel soluble epoxide hydrolase vaccine protects murine cardiac muscle against myocardial infarction. Scientific Reports, 2022, 12, 6923.	3.3	2
6	Blood pressure fluctuations and the indoor environment in a highly insulated and airtight model house during the cold winter season. Hypertension Research, 2022, 45, 1217-1219.	2.7	5
7	Management guideline for Werner syndrome 2020. 7. Skin ulcer associated with Werner syndrome: Dermatological treatment. Geriatrics and Gerontology International, 2021, 21, 160-162.	1.5	5
8	Management guideline for <scp>W</scp> erner syndrome 2020. 4. <scp>O</scp> steoporosis associated with <scp>W</scp> erner syndrome. Geriatrics and Gerontology International, 2021, 21, 146-149.	1.5	6
9	Management guideline for Werner syndrome 2020 8. Calcification in tendons associated with Werner syndrome. Geriatrics and Gerontology International, 2021, 21, 163-165.	1.5	5
10	Management guideline for Werner syndrome 2020 1. Dyslipidemia and fatty liver associated with Werner syndrome. Geriatrics and Gerontology International, 2021, 21, 133-138.	1.5	4
11	Management guideline for <scp>Werner</scp> syndrome 2020. 3. Diabetes associated with <scp>Werner</scp> syndrome. Geriatrics and Gerontology International, 2021, 21, 142-145.	1.5	8
12	Management guideline for Werner syndrome 2020. 2. Sarcopenia associated with Werner syndrome. Geriatrics and Gerontology International, 2021, 21, 139-141.	1.5	5
13	Management guideline for <scp>W</scp> erner syndrome 2020. <scp>5</scp> . <scp>I</scp> nfection associated with <scp>W</scp> erner syndrome. Geriatrics and Gerontology International, 2021, 21, 150-152.	1.5	3
14	Management guideline for W erner syndrome 2020. 6. Skin ulcers associated with W erner syndrome: Prevention and nonâ€surgical and surgical treatment. Geriatrics and Gerontology International, 2021, 21, 153-159.	1.5	10
15	SARS-CoV-2-induced humoral immunity through B cell epitope analysis in COVID-19 infected individuals. Scientific Reports, 2021, 11, 5934.	3.3	26
16	Development of COVID-19 vaccines utilizing gene therapy technology. International Immunology, 2021, 33, 521-527.	4.0	19
17	Prevention of Acute Lung Injury by a Novel CD14-Inhibitory Receptor Activator of the NF-κB Ligand Peptide in Mice. ImmunoHorizons, 2021, 5, 438-447.	1.8	5
18	Development of anti-thrombotic vaccine against human S100A9 in rhesus monkey. Scientific Reports, 2021, 11, 11472.	3.3	4

#	Article	IF	CITATIONS
19	An infectivity-enhancing site on the SARS-CoV-2 spike protein targeted by antibodies. Cell, 2021, 184, 3452-3466.e18.	28.9	205
20	Therapeutic vaccine for chronic diseases after the COVID-19 Era. Hypertension Research, 2021, 44, 1047-1053.	2.7	7
21	Prevention of vascular dementia via immunotherapeutic blockade of renin-angiotensin system in a rat model. Brain Research, 2021, 1772, 147667.	2.2	4
22	Development of anti-thrombotic and hypertensive vaccine for prevention of ischemic stroke. Japanese Journal of Thrombosis and Hemostasis, 2021, 32, 284-288.	0.1	0
23	A novel angiotensin II peptide vaccine without an adjuvant in mice. Journal of Hypertension, 2021, 39, 181-189.	0.5	3
24	Study protocol for a randomized, open-label, non-controlled Phase I/II Study to assess safety and immunogenicity of twice or three times dosing of intramuscular COVID-19 DNA vaccine in healthy adults. Translational and Regulatory Sciences, 2021, , .	0.2	0
25	Identification of conserved SARS-CoV-2 spike epitopes that expand public cTfh clonotypes in mild COVID-19 patients. Journal of Experimental Medicine, 2021, 218, .	8.5	24
26	Vaccine targeting ANGPTL3 ameliorates dyslipidemia and associated diseases in mouse models of obese dyslipidemia and familial hypercholesterolemia. Cell Reports Medicine, 2021, 2, 100446.	6.5	16
27	Senolytic vaccination improves normal and pathological age-related phenotypes and increases lifespan in progeroid mice. Nature Aging, 2021, 1, 1117-1126.	11.6	87
28	Novel properties of myoferlin in glucose metabolism via pathways involving modulation of adipose functions. FASEB Journal, 2020, 34, 2792-2811.	0.5	3
29	Cellular senescence and senescenceâ€associated T cells as a potential therapeutic target. Geriatrics and Gerontology International, 2020, 20, 97-100.	1.5	20
30	Stable Immune Response Induced by Intradermal DNA Vaccination by a Novel Needleless Pyro-Drive Jet Injector. AAPS PharmSciTech, 2020, 21, 19.	3.3	25
31	Prevention of Progression of Aortic Aneurysm by Peptide Vaccine Against Ang II (Angiotensin II) in a Rat Model. Hypertension, 2020, 76, 1879-1888.	2.7	7
32	Antiproliferative Effects of Monoclonal Antibodies against (Pro)Renin Receptor in Pancreatic Ductal Adenocarcinoma. Molecular Cancer Therapeutics, 2020, 19, 1844-1855.	4.1	10
33	Progress of Gene Therapy in Cardiovascular Disease. Hypertension, 2020, 76, 1038-1044.	2.7	16
34	The CD153 vaccine is a senotherapeutic option for preventing the accumulation of senescent T cells in mice. Nature Communications, 2020, 11, 2482.	12.8	64
35	Development of an IL-17A DNA Vaccine to Treat Systemic Lupus Erythematosus in Mice. Vaccines, 2020, 8, 83.	4.4	4
36	Time gap between the onset and diagnosis in Werner syndrome: a nationwide survey and the 2020 registry in Japan. Aging, 2020, 12, 24940-24956.	3.1	20

#	Article	IF	CITATIONS
37	Combined Analysis of Clinical Data on HGF Gene Therapy to Treat Critical Limb Ischemia in Japan. Current Gene Therapy, 2020, 20, 25-35.	2.0	14
38	Future Directions of Therapeutic Vaccines for Chronic Diseases. Circulation Journal, 2020, 84, 1895-1902.	1.6	5
39	Preventative effects of the partial RANKL peptide MHP1-AcN in a mouse model of imiquimod-induced psoriasis. Scientific Reports, 2019, 9, 15434.	3.3	10
40	Temporal and spatial profile of polymorphonuclear myeloid-derived suppressor cells (PMN-MDSCs) in ischemic stroke in mice. PLoS ONE, 2019, 14, e0215482.	2.5	20
41	Peptide vaccine for semaphorin3E ameliorates systemic glucose intolerance in mice with dietary obesity. Scientific Reports, 2019, 9, 3858.	3.3	4
42	A vaccine targeting blood clot formation: what is the potential?. Expert Review of Vaccines, 2019, 18, 419-421.	4.4	0
43	AJP001, a novel helper Tâ€cell epitope, induces a humoral immune response with activation of innate immunity when included in a peptide vaccine. FASEB BioAdvances, 2019, 1, 760-772.	2.4	2
44	Pathophysiological significance of cylindromatosis in the vascular endothelium and macrophages for the initiation of age-related atherogenesis. Biochemical and Biophysical Research Communications, 2019, 508, 1168-1174.	2.1	2
45	Dysfunctional high density lipoprotein failed to rescue the function of oxidized low density lipoprotein-treated endothelial progenitor cells: a novel index for the prediction of HDL functionality. Translational Research, 2019, 205, 17-32.	5.0	13
46	Investigatorâ€initiated clinical study of a functional peptide, SRâ€0379, for limb ulcers of patients with Werner syndrome as a pilot study. Geriatrics and Gerontology International, 2019, 19, 1118-1123.	1.5	6
47	Closing: Clinical Applications of Therapeutic Vaccines in theÂNear Future. , 2019, , 73-79.		0
48	A Vaccine for Ischemic Stroke. , 2019, , 21-32.		0
49	Physician-initiated clinical study of limb ulcers treated with a functional peptide, SR-0379: from discovery to a randomized, double-blind, placebo-controlled trial. Npj Aging and Mechanisms of Disease, 2018, 4, 2.	4.5	8
50	Therapeutic Vaccines for Hypertension: a New Option for Clinical Practice. Current Hypertension Reports, 2018, 20, 22.	3.5	9
51	Development of a novel RANKL-based peptide, microglial healing peptide1-AcN (MHP1-AcN), for treatment of ischemic stroke. Scientific Reports, 2018, 8, 17770.	3.3	16
52	Recent Advances in Therapeutic Vaccines to Treat Hypertension. Hypertension, 2018, 72, 1031-1036.	2.7	20
53	Therapeutic Vaccine Against S100A9 (S100 Calcium-Binding Protein A9) Inhibits Thrombosis Without Increasing the Risk of Bleeding in Ischemic Stroke in Mice. Hypertension, 2018, 72, 1355-1364.	2.7	35
54	Angiotensinâ€converting enzyme 2 deficiency accelerates and angiotensin 1â€7 restores ageâ€related muscle weakness in mice. Journal of Cachexia, Sarcopenia and Muscle, 2018, 9, 975-986.	7.3	37

#	Article	IF	CITATIONS
55	Therapeutic Effects of Systemic Administration of the Novel RANKL-Modified Peptide, MHP1, for Ischemic Stroke in Mice. BioMed Research International, 2018, 2018, 1-8.	1.9	8
56	Development of vaccine for dyslipidemia targeted to a proprotein convertase subtilisin/kexin type 9 (PCSK9) epitope in mice. PLoS ONE, 2018, 13, e0191895.	2.5	46
57	Vaccines and Biologics for Hypertension and Diabetes. Proceedings for Annual Meeting of the Japanese Pharmacological Society, 2018, WCP2018, SY39-2.	0.0	0
58	A peptide vaccine targeting angiotensin II attenuates the cardiac dysfunction induced by myocardial infarction. Scientific Reports, 2017, 7, 43920.	3.3	25
59	Design of therapeutic vaccines as a novel antibody therapy for cardiovascular diseases. Journal of Cardiology, 2017, 70, 201-205.	1.9	5
60	Physicianâ€initiated firstâ€inâ€human clinical study using a novel angiogenic peptide, AG30/5C, for patients with severe limb ulcers. Geriatrics and Gerontology International, 2017, 17, 2150-2156.	1.5	6
61	Glial fibrillary acidic protein (GFAP) is a novel biomarker for the prediction of autoimmune diabetes. FASEB Journal, 2017, 31, 4053-4063.	0.5	16
62	Angiotensin II Peptide Vaccine Protects Ischemic Brain Through Reducing Oxidative Stress. Stroke, 2017, 48, 1362-1368.	2.0	29
63	Evaluating the potential of the GFAPâ€KLH immuneâ€ŧolerizing vaccine for type 1 diabetes in mice. FEBS Letters, 2017, 591, 129-136.	2.8	5
64	Association between renin–angiotensin–aldosterone system blockade and future osteoporotic fracture risk in hypertensive population. Medicine (United States), 2017, 96, e8331.	1.0	10
65	A novel lipoprotein (a) lowering drug, D-47, decreases neointima thickening after vascular injury. Journal of Medical Investigation, 2017, 64, 64-67.	0.5	2
66	A Novel Therapeutic Peptide as a Partial Agonist of RANKL in Ischemic Stroke. Scientific Reports, 2016, 6, 38062.	3.3	28
67	RANKL system in vascular and valve calcification with aging. Inflammation and Regeneration, 2016, 36, 10.	3.7	22
68	A Model of Stroke and Vascular Injury in the Brain. , 2016, , 263-274.		0
69	Evaluation of the Genetic Risk of Hypertension-Related Diseases. Circulation Journal, 2015, 79, 756-757.	1.6	1
70	Low alpha-synuclein levels in the blood are associated with insulin resistance. Scientific Reports, 2015, 5, 12081.	3.3	36
71	The Biphasic Effects of Oxidized-Low Density Lipoprotein on the Vasculogenic Function of Endothelial Progenitor Cells. PLoS ONE, 2015, 10, e0123971.	2.5	22
72	Long-Term Reduction of High Blood Pressure by Angiotensin II DNA Vaccine in Spontaneously Hypertensive Rats. Hypertension, 2015, 66, 167-174.	2.7	37

#	Article	IF	CITATIONS
73	Continuous infusion of angiotensin II modulates hypertrophic differentiation and apoptosis of chondrocytes in cartilage formation in a fracture model mouse. Hypertension Research, 2015, 38, 382-393.	2.7	12
74	Teneligliptin: expectations for its pleiotropic action. Expert Opinion on Pharmacotherapy, 2015, 16, 417-426.	1.8	35
75	Effect of angiotensin <scp>II</scp> receptor blocker, olmesartan, on turnover of bone metabolism in bedridden elderly hypertensive women with disuse syndrome. Geriatrics and Gerontology International, 2015, 15, 1064-1072.	1.5	19
76	Development of DNA vaccines as an anti-hypertensive therapy or for anti-angiogenesis. Expert Opinion on Biological Therapy, 2015, 15, 431-436.	3.1	3
77	Oxidized LDL (oxLDL) activates the angiotensin II type 1 receptor by binding to the lectin-like oxLDL receptor. FASEB Journal, 2015, 29, 3342-3356.	0.5	44
78	Molecular mechanism of vascular calcification with aging. Japanese Journal of Thrombosis and Hemostasis, 2015, 26, 284-289.	0.1	0
79	Novel Anti-Microbial Peptide SR-0379 Accelerates Wound Healing via the PI3 Kinase/Akt/mTOR Pathway. PLoS ONE, 2014, 9, e92597.	2.5	43
80	Peptide Vaccines for Hypertension and Diabetes Mellitus. Vaccines, 2014, 2, 832-840.	4.4	6
81	Therapeutic Vaccines for Hypertension and Dyslipidemia. International Heart Journal, 2014, 55, 96-100.	1.0	16
82	OPG/RANKL/RANK axis is a critical inflammatory signaling system in ischemic brain in mice. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 8191-8196.	7.1	93
83	Prevention of Neointimal Formation After Angioplasty Using Nuclear Factor-ήB Decoy Oligodeoxynucleotide-Coated Balloon Catheter in Rabbit Model. Circulation: Cardiovascular Interventions, 2014, 7, 787-796.	3.9	13
84	Long-term expression of periostin during the chronic stage of ischemic stroke in mice. Hypertension Research, 2014, 37, 494-499.	2.7	15
85	Therapeutic vaccine against DPP4 improves glucose metabolism in mice. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, E1256-63.	7.1	39
86	The dipeptidyl peptidase-4 inhibitor teneligliptin improved endothelial dysfunction and insulin resistance in the SHR/NDmcr-cp rat model of metabolic syndrome. Hypertension Research, 2014, 37, 629-635.	2.7	34
87	Research for Localized High-Efficient Gene Transfer by the Magnetic Force Control Using High Temperature Superconducting Bulk Magnet. IEEE Transactions on Applied Superconductivity, 2014, 24, 1-5.	1.7	2
88	Alpha-synuclein elicits glucose uptake and utilization in adipocytes through the Gab1/PI3K/Akt transduction pathway. Cellular and Molecular Life Sciences, 2013, 70, 1123-1133.	5.4	33
89	Do Angiotensin Receptor Blockers Protect Against Alzheimer's Disease?. Drugs and Aging, 2013, 30, 367-372	2.7	15
90	Cross-Talk of Receptor Activator of Nuclear Factor-κB Ligand Signaling With Renin–Angiotensin System in Vascular Calcification. Arteriosclerosis, Thrombosis, and Vascular Biology, 2013, 33, 1287-1296.	2.4	53

#	Article	IF	CITATIONS
91	Development of novel DNA vaccine for VEGF in murine cancer model. Scientific Reports, 2013, 3, 3380.	3.3	16
92	The Mechanism of White and Brown Adipocyte Differentiation. Diabetes and Metabolism Journal, 2013, 37, 85.	4.7	34
93	The Transcription Factors Tbx18 and Wt1 Control the Epicardial Epithelial-Mesenchymal Transition through Bi-Directional Regulation of Slug in Murine Primary Epicardial Cells. PLoS ONE, 2013, 8, e57829.	2.5	63
94	Decrease in Blood Pressure and Regression of Cardiovascular Complications by Angiotensin II Vaccine in Mice. PLoS ONE, 2013, 8, e60493.	2.5	44
95	Potential Effect of Angiotensin II Receptor Blockade in Adipose Tissue and Bone. Current Pharmaceutical Design, 2013, 19, 3049-3053.	1.9	14
96	Essential Role for miR-196a in Brown Adipogenesis of White Fat Progenitor Cells. PLoS Biology, 2012, 10, e1001314.	5.6	209
97	Role of Central Nervous System Periostin in Cerebral Ischemia. Stroke, 2012, 43, 1108-1114.	2.0	37
98	HIG1, a novel regulator of mitochondrial γâ€secretase, maintains normal mitochondrial function. FASEB Journal, 2012, 26, 2306-2317.	0.5	39
99	Cilnidipine, but not amlodipine, ameliorates osteoporosis in ovariectomized hypertensive rats through inhibition of the N-type calcium channel. Hypertension Research, 2012, 35, 77-81.	2.7	21
100	Modification of a novel angiogenic peptide, AG30, for the development of novel therapeutic agents. Journal of Cellular and Molecular Medicine, 2012, 16, 1629-1639.	3.6	26
101	Links Between Hypertension and Osteoporosis: Benidipine Ameliorates Osteoporosis in Ovariectomized Hypertensive Rats Through Promotion of Osteoblast Proliferation and Inhibition of Osteoclast Differentiation. Current Cardiovascular Risk Reports, 2012, 6, 274-280.	2.0	5
102	Nifedipine prevents hepatic fibrosis in a non-alcoholic steatohepatitis model induced by an L-methionine-and choline-deficient diet. Molecular Medicine Reports, 2011, 5, 37-40.	2.4	11
103	Can Forkhead Box P1 be a novel therapeutic target for atherosclerosis?. Atherosclerosis, 2011, 218, 26-27.	0.8	0
104	Obesity and Gastrointestinal Hormones-Dual Effect of Angiotensin II Receptor Blockade and a Partial Agonist of PPAR-γ. Current Vascular Pharmacology, 2011, 9, 162-166.	1.7	13
105	New Concept of Vascular Calcification and Metabolism. Current Vascular Pharmacology, 2011, 9, 124-127.	1.7	14
106	Inorganic polyphosphate differentiates human mesenchymal stem cells into osteoblastic cells. Journal of Bone and Mineral Metabolism, 2010, 28, 418-423.	2.7	32
107	Cold shock domain protein A (CSDA) overexpression inhibits tumor growth and lymph node metastasis in a mouse model of squamous cell carcinoma. Clinical and Experimental Metastasis, 2010, 27, 539-547.	3.3	16
108	Estrogen Inhibits Vascular Calcification via Vascular RANKL System. Circulation Research, 2010, 107, 466-475.	4.5	173

#	Article	IF	CITATIONS
109	Fluvastatin improves osteoporosis in fructose-fed insulin resistant model rats through blockade of the classical mevalonate pathway and antioxidant action. International Journal of Molecular Medicine, 2009, 23, 581-8.	4.0	16
110	New Treatment of Periodontal Diseases by Using NF-κB Decoy Oligodeoxynucleotides <i>via</i> Prevention of Bone Resorption and Promotion of Wound Healing. Antioxidants and Redox Signaling, 2009, 11, 2065-2075.	5.4	35
111	FHL-2 Suppresses VEGF-Induced Phosphatidylinositol 3-Kinase/Akt Activation via Interaction With Sphingosine Kinase-1. Arteriosclerosis, Thrombosis, and Vascular Biology, 2009, 29, 909-914.	2.4	32
112	Prevention of osteoporosis by angiotensin-converting enzyme inhibitor in spontaneous hypertensive rats. Hypertension Research, 2009, 32, 786-790.	2.7	59
113	Zyxin Mediates Actin Fiber Reorganization in Epithelial–Mesenchymal Transition and Contributes to Endocardial Morphogenesis. Molecular Biology of the Cell, 2009, 20, 3115-3124.	2.1	48
114	Development of a novel antimicrobial peptide, AGâ€30, with angiogenic properties. Journal of Cellular and Molecular Medicine, 2009, 13, 535-546.	3.6	27
115	Vascular protective effects of ezetimibe in ApoE-deficient mice. Atherosclerosis, 2009, 203, 51-58.	0.8	47
116	PITAVASTATIN SUPPRESSES FORMATION AND PROGRESSION OF CEREBRAL ANEURYSMS THROUGH INHIBITION OF THE NUCLEAR FACTOR κB PATHWAY. Neurosurgery, 2009, 64, 357-366.	1.1	79
117	Cold shock domain protein A, novel endogenous regulator of angiogenesis in heart. Journal of Molecular and Cellular Cardiology, 2008, 45, S7-S8.	1.9	0
118	Potential Role of CYLD (Cylindromatosis) as a Deubiquitinating Enzyme in Vascular Cells. American Journal of Pathology, 2008, 172, 818-829.	3.8	34
119	Angiotensin II accelerates osteoporosis by activating osteoclasts. FASEB Journal, 2008, 22, 2465-2475.	0.5	243
120	Ubiquitin Carboxyl-Terminal Hydrolase L1, a Novel Deubiquitinating Enzyme in the Vasculature, Attenuates NF-κB Activation. Arteriosclerosis, Thrombosis, and Vascular Biology, 2007, 27, 2184-2190.	2.4	66
121	Gene Polymorphism of Myospryn (Cardiomyopathy-Associated 5) Is Associated with Left Ventricular Wall Thickness in Patients with Hypertension. Hypertension Research, 2007, 30, 1239-1246.	2.7	31
122	NF-κB Is a Key Mediator of Cerebral Aneurysm Formation. Circulation, 2007, 116, 2830-2840.	1.6	218
123	Involvement of Î ³ -secretase in postnatal angiogenesis. Biochemical and Biophysical Research Communications, 2007, 363, 584-590.	2.1	10
124	Increase in nuclease resistance and incorporation of NFâ€₽B decoy oligodeoxynucleotides by modification of the 3â€2â€ŧerminus. Journal of Gene Medicine, 2007, 9, 812-819.	2.8	25
125	Adipose Tissue-Derived Stromal Cells as a Novel Option for Regenerative Cell Therapy. Journal of Atherosclerosis and Thrombosis, 2006, 13, 77-81.	2.0	326
126	Favorable effects of statins beyond lipid lowering. Future Lipidology, 2006, 1, 75-80.	0.5	0

#	Article	IF	CITATIONS
127	Model of Vasculogenesis from Embryonic Stem Cells for Vascular Research and Regenerative Medicine. Hypertension, 2006, 48, 112-119.	2.7	30
128	Anti-Oxidant Gene Therapy by NFkB Decoy Oligodeoxynucleotide. Current Pharmaceutical Biotechnology, 2006, 7, 95-100.	1.6	16
129	Development of High-Throughput Functional Screening of Therapeutic Genes, Using a Hemagglutinating Virus of Japan Envelope Vector. Human Gene Therapy, 2006, 17, 470-475.	2.7	13
130	Transfection of Human Hepatocyte Growth Factor Gene Ameliorates Secondary Lymphedema via Promotion of Lymphangiogenesis. Circulation, 2006, 114, 1177-1184.	1.6	93
131	Novel Drug Delivery System by Surface Modified Magnetic Nanoparticles. Journal of Nanoscience and Nanotechnology, 2006, 6, 3269-3276.	0.9	16
132	Novel Autologous Cell Therapy in Ischemic Limb Disease Through Growth Factor Secretion by Cultured Adipose Tissue–Derived Stromal Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2005, 25, 2542-2547.	2.4	534
133	Magnetic nanoparticles with surface modification enhanced gene delivery of HVJ-E vector. Biochemical and Biophysical Research Communications, 2005, 334, 1121-1126.	2.1	144
134	NADPH oxidase-derived superoxide anion mediates angiotensin II-induced cardiac hypertrophy. Journal of Molecular and Cellular Cardiology, 2003, 35, 851-859.	1.9	241
135	Hepatocyte Growth Factor Prevents Endothelial Cell Death Through Inhibition of bax Translocation From Cytosol to Mitochondrial Membrane. Diabetes, 2002, 51, 2604-2611.	0.6	73
136	Estrogen Activates Phosphatases and Antagonizes Growth-Promoting Effect of Angiotensin II. Hypertension, 2002, 39, 41-45.	2.7	65
137	Tumor Necrosis Factor-α Inhibits Growth Factor–Mediated Cell Proliferation Through SHP-1 Activation in Endothelial Cells. Arteriosclerosis, Thrombosis, and Vascular Biology, 2002, 22, 238-242.	2.4	47
138	Phosphorylation of p38 Mitogen-Activated Protein Kinase Downstream of Bax-Caspase-3 Pathway Leads to Cell Death Induced by High <scp>d</scp> -Glucose in Human Endothelial Cells. Diabetes, 2001, 50, 1472-1481.	0.6	147
139	Therapeutic Angiogenesis Induced by Human Hepatocyte Growth Factor Gene in Rat Diabetic Hind Limb Ischemia Model. Circulation, 2001, 104, 2344-2350.	1.6	184
140	Mitogenic and Antiapoptotic Actions of Hepatocyte Growth Factor Through ERK, STAT3, and Akt in Endothelial Cells. Hypertension, 2001, 37, 581-586.	2.7	146
141	Involvement of Bradykinin and Nitric Oxide in Leptin-Mediated Glucose Uptake in Skeletal Muscle. Endocrinology, 2001, 142, 608-612.	2.8	42
142	Statins as antioxidant therapy for preventing cardiac myocyte hypertrophy. Journal of Clinical Investigation, 2001, 108, 1429-1437.	8.2	429
143	Involvement of Bradykinin and Nitric Oxide in Leptin-Mediated Glucose Uptake in Skeletal Muscle. Endocrinology, 2001, 142, 608-612.	2.8	12
144	Anti-apoptotic action of hepatocyte growth factor through mitogen-activated protein kinase on human aortic endothelial cells. Journal of Hypertension, 2000, 18, 1411-1420.	0.5	27

#	Article	IF	CITATIONS
145	Hypoxia-Induced Endothelial Apoptosis Through Nuclear Factor-κB (NF-κB)–Mediated bcl-2 Suppression. Circulation Research, 2000, 86, 974-981.	4.5	177
146	Ribozyme Oligonucleotides Against Transforming Growth Factor-Î ² Inhibited Neointimal Formation After Vascular Injury in Rat Model. Circulation, 2000, 102, 1308-1314.	1.6	97
147	Transfection of Antisense <i>p53</i> Tumor Suppressor Gene Oligodeoxynucleotides Into Rat Carotid Artery Results in Abnormal Growth of Vascular Smooth Muscle Cells. Circulation, 2000, 101, 1447-1452.	1.6	35
148	Potential Contribution of a Novel Antifibrotic Factor, Hepatocyte Growth Factor, to Prevention of Myocardial Fibrosis by Angiotensin II Blockade in Cardiomyopathic Hamsters. Circulation, 2000, 102, 246-252.	1.6	182